Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) Trial
TRACK will evaluate the effect of low dose rivaroxaban on major adverse cardiovascular events in participants with CKD stages 4 and 5 and dialysis-dependent kidney failure, and elevated cardiovascular risk.
Authors
- Jeffrey T. Ha (ORCID: https://orcid.org/0000-0002-8558-1697)
- J. Menne
- Séverine Bompoint
- Shilpanjali Jesudason (ORCID: https://orcid.org/0000-0001-9695-0761)
- David Collister
- Min Jun
- Ahmed M. Shaman (ORCID: https://orcid.org/0000-0002-0718-8144)
- Adrien Flahault (ORCID: https://orcid.org/0000-0003-4632-6332)
- Geot Wong Muh
- Jenny Landrigan
- Vlado Perkovic
- Habib Skhiri
- Maha Al Ammari
- Sunil Badve
- Lv Jicheng
- Enmoore Lin
- Anushka Patel
- Adrian Liew
- Amit X. Garg
- Patrick Rossignol
- Meg J. Jardine
- Hiddo J.L. Heerspink
- for the TRACK Trial Investigators
- David C. Wheeler
- Li Zuo
- Lily Mushahar
- Craig S. Anderson
- Laurent Billot
- Raja Ramachandran
- Martin Gallagher
- Michael Walsh
- Helen Pilmore
- John W. Eikelboom
- An S. De Vriese
- Vivekanand Jha
Institutions
- Western University (CA)
- The University of Sydney (AU)
- Royal Adelaide Hospital (AU)
- University of Auckland (NZ)
- University of Alberta (CA)
- Inserm (FR)
- Manipal Academy of Higher Education (IN)
- University of Monastir (TN)
- University of Groningen (NL)
- Peking University (CN)
- Fudan University (CN)
- Concord Repatriation General Hospital (AU)
- London Health Sciences Centre (CA)
- Princess Grace Hospital Centre (MC)
- Auckland City Hospital (NZ)
- King Saud University (SA)
- King Abdulaziz Medical City (SA)
- Mount Elizabeth Novena Hospital (SG)
- Population Health Research Institute (CA)
- UNSW Sydney (AU)
- Ghent University (BE)
- Shanghai Institute for Science of Science (CN)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Hospital Tuanku Ja’afar (MY)
- Klinikum Region Hannover (DE)
- The George Institute for Global Health (AU)
- Canadian VIGOUR Centre (CA)
- St George Hospital (AU)
- AZ Sint-Jan (BE)
- Peking University People's Hospital (CN)
- Peking University First Hospital (CN)
- Impact (CA)
- Shanghai Center for Brain Science and Brain-Inspired Technology (CN)
- French Clinical Research Infrastructure Network (FR)
- National Health and Medical Research Council (AU)
- University College London (GB)
- Post Graduate Institute of Medical Education and Research (IN)
- Imperial College London (GB)
- The University of Adelaide (AU)
- Hamilton Health Sciences (CA)
- University of Glasgow (GB)
- Université de Lorraine (FR)
- McMaster University (CA)
Publication Details
- Journal
- American Journal of Nephrology
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1159/000550796
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bayer
- Deutsche Forschungsgemeinschaft
- King Saud University
- Universiti Malaya
- Universiti Kebangsaan Malaysia
- King Abdullah International Medical Research Center
- Fu Jen Catholic University
- Medical Research Council
- National Health and Medical Research Council